Loading the player...
Information
Nephrology for the Primary Care Provider
Chronic kidney disease (CKD) is a common, yet under recognized problem in America. In the last 5 years, a number of studies have been published describing new therapies to combat CKD and lower the rate of end stage kidney disease. This presentation will cover these studies regarding SGLT2 inhibitors, mineralocorticoid receptor antagonists, and GLP-1 agonists to name a few. The goal is to provide practical and concise information, such that physician inertia in prescribing these therapies can be overcome.
Learning Objectives
Following the completion of this lecture, the participant will be able to:
- Discuss the use of SGLT2 inhibitors in CKD
- Discuss the role of mineral corticoid receptor antagonists in CKD
- Discuss the role of GLP-1 agonists in CKD
- Review the relevant labs that need to be check when confronting CKD in the outpatient setting
Corey Cavanaugh, DO
Dr. Cavanaugh is a nephrologist specializing in glomerular diseases or diseases that impact the kidneys. These include lupus, vasculitis, membranous nephropathy and focal segmental glomerulosclerosis (FSGS), among others.
Cavanaugh attended medical school at the Heritage College of Osteopathic Medicine at Ohio University, where he met his wife. They both completed their internal medicine training at the University of Louisville. Cavanaugh then went on to pursue a nephrology fellowship at Yale University before settling in Virginia. Since arriving at the University of Virginia in August of 2019, he has
established a dedicated multidisciplinary glomerular disease clinic, as well as a combined rheumatology-nephrology clinic.
Dr. Cavanaugh has no disclosures
